OncoMark to Present Two Studies on Prognostic Test for Early Stage Breast Cancer at ASCO 2018 in Chicago
Presentations will highlight the clinical performance of the OncoMasTR test in the TransATAC and TAILORx tissue bank cohorts
OncoMark Ltd, today announced that the results from two studies on the clinical performance of OncoMasTR, the company’s prognostic test for early stage breast cancer, will be presented at the 2018 American Society for Clinical Oncology (ASCO) annual meeting. This meeting will be held in Chicago from 1-5 June.
OncoMark, an Irish diagnostics company, is focused on the development of novel panels of cancer biomarkers to aid treatment decisions for cancer patients.
Speaking in advance of the annual meeting Des O’Leary, CEO, OncoMark, said, "We are very excited that the results from two significant studies in TransATAC and TAILORx tissue bank cohorts will be presented at this year’s ASCO meeting. The presentations will highlight the performance of our novel OncoMasTR test in identifying women who can safely avoid unnecessary chemotherapy in the treatment of oestrogen receptor positive breast cancer.”
He added, "The data presented will provide the basis for our planned CE Marking and launch of the OncoMasTR test scheduled for Q3 2018.”
Details of the two poster presentations on OncoMark’s OncoMasTR test at the 2018 ASCO meeting are as follows;
- Evaluation of the OncoMasTR Prognostic Signature in Postmenopausal Women with Primary ER-positive Breast Cancer by Dr Ivana Sestak, Centre for Cancer Prevention, Wolfson Institute of Preventative Medicine, Queen Mary University of London.
Session Breast Cancer- Local, Regional, Adjuvant: Poster Board #45, Abstract Number #553: Saturday 2 June, 8:00am – 11:30am.
- Comparison of the Prognostic Performance Between OncoMasTR and OncotypeDx Multigene Signatures in Hormone-Receptor Positive, HER2-Negative, Lymph Node-Negative Breast Cancer by Professor Catherine M. Kelly, FRCP, Mater Misericordiae University Hospital, Dublin.
Session - Tumor Biology: Poster Board #187, Abstract Number #12074: Monday 4 June, 1:15pm – 4:45pm.